NCT05494060View on ClinicalTrials.gov

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2027

Conditions
CarcinomaGastrointestinal DiseasesStomach CancerGastroesophageal-junction CancerDigestive System DiseasesGastric CancerGastrointestinal Neoplasms
Interventions
DRUG

Anlotinib hydrochloride capsule

Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；

DRUG

Penpulimab Injection

Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days

DRUG

XELOX

Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w

Trial Locations (1)

210029

RECRUITING

Jiangsu Province Hospital, Nanjing

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER